The Food and Drug Administration on Monday approved Merck's shot designed to protect infants from respiratory syncytial virus during their first season of the virus, bringing to market a rival to a similar treatment from Sanofi and AstraZeneca.The decision will allow the company to launch the drug, which will be marketed as Enflonsia, ahead of the RSV season that typically kicks off around fall and winter and lasts through the spring. Merck said in a release that it expects orders for the shot to begin in J ...

NEW YORK, June 7, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sanofi ("Sanofi" or the "Company") (NASDAQ: SNY). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.  The investigation concerns whether Sanofi and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action] On May 30, 2025, Sanofi issued a pres ...

NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Sanofi (“Sanofi” or the “Company”) (NASDAQ: SNY).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.    The investigation concerns whether Sanofi and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On May 30, 2025, Sanofi ...

Core Points - Sanofi is launching its global employee shareholder plan, Action 2025, on June 10, 2025, for approximately 70,000 employees across 55 countries, marking the program's 11th year [1][2] - In 2024, over 32,000 employees, representing 40% of the workforce, participated in the program, and nearly 90,000 current or former employees now hold about 2.55% of Sanofi's capital [1][2] Employee Participation - The subscription price for shares will be set at €72.97, which is a 20% discount based on the average of the 20 opening prices from May 7 to June 3, 2025 [2] - Employees can purchase up to 1,500 shares, with a maximum payment not exceeding 25% of their gross annual salary, and for every five shares subscribed, one free matching share will be offered, up to a maximum of four matching shares per employee [2][3] Subscription Details - Eligible employees must have three months of employment by the closing date of the offer period, with the subscription period running from June 10 to June 30, 2025 [3] - The total number of shares offered is limited to 1% of Sanofi's share capital as of January 29, 2025, after accounting for a previous capital increase reserved for employees [4] Share Characteristics - The new shares will be fully fungible with existing shares and will acquire dividend rights starting January 1, 2025, with voting rights exercised directly by employees [5] - Shares subscribed in France must be held for approximately five years, while those subscribed outside France may have a holding period of three years, depending on local regulations [6] Trading and Compliance - Admission of the shares to trading on the Euronext Paris market will be requested after the completion of the capital increase [7] - The offer will only be made in countries where all necessary registration and notification procedures have been completed [9]

Key Takeaways Sanofi's rilzabrutinib receives FDA orphan drug designation for SCD, its fourth such indication. Preclinical data show rilzabrutinib reduced vaso-occlusion and inflammation in SCD mouse models. Rilzabrutinib is also under FDA review for ITP, with a decision expected by August 29, 2025.Sanofi (SNY) announced that the FDA has granted orphan drug designation to its investigational BTK inhibitor, rilzabrutinib, for sickle cell disease (SCD). The candidate exerts its effects through multi-immune ...

ASCO: new Sarclisa data support subcutaneous administration with on-body injector New data from two clinical studies demonstrated that Sarclisa administered subcutaneously via an investigational on-body injector shortened treatment time to minutes with similar efficacy and safety compared to intravenous infusionStudies used Enable Injections’ enFuse® on-body injector, an automated hands-free injectorData will form the basis of global regulatory submissions across all currently approved lines of treatment P ...

赛诺菲(SNY.US)近日宣布拟以91亿美元收购Blueprint Medicines(BPMC.US)，高盛对此表示，这笔交易 旨在通过整合Blueprint的罕见病与免疫学管线资产，帮助赛诺菲填补其核心产品Dupixent在2031/32年专 利到期后的利润缺口。因此，该行维持赛诺菲"中性"评级，目标价117欧元(ADR67美元)。 高盛在一份报告中指出，根据条款，赛诺菲将以每股129美元的现金(较5月30日收盘价溢价27%)收购 Blueprint，预付金额达91亿美元。若Blueprint的免疫学候选药物BLU-808研发成功，股东还可获得两项 每股2美元和4美元的额外或有价值权(CVR)，总交易额最高可达95亿美元。此次交易预计将于2025年第 三季度完成。 本次收购的核心资产包括已获批的酪氨酸激酶抑制剂Ayvakit(用于治疗肥大细胞相关罕见病)及在研药物 BLU-808(针对非突变KIT，适应症为慢性荨麻疹、过敏性哮喘等免疫疾病)等。据Visible Alpha预测， Ayvakit的2033年峰值销售额可达23.5亿欧元(毛利率高达95%);BLU-808的2033年峰值销售额预期可达27 亿 ...

Key Takeaways Sanofi will acquire BPMC for up to $9.5B, including a 27% premium and CVRs tied to BLU-808 milestones. The deal adds Ayvakit, which saw Q1 2025 sales of $149.4M and is projected to hit $2B by 2030. SNY aims to reduce Dupixent reliance by expanding its immunology portfolio through acquisitions.Sanofi (SNY) announced that it has entered into a definitive agreement to acquire Blueprint Medicines (BPMC) for a total deal value of up to $9.5 billion. Following the announcement, shares of BPMC are ...

STAT6 is a key transcription factor within the IL4/IL13 signaling pathways which act as drivers of inflammation in allergic conditions Nurix to receive a $15 million license extension fee from Sanofi under its 2019 collaboration agreement, bringing the total amount received by Nurix under this collaboration to date to $127 million Nurix is eligible for an additional $465 million in development, regulatory and commercial milestones associated with the STAT6 program as well as potential future royalties and ...

--Completion of GLP toxicology studies associated with a $50 million payment to Recludix under the collaboration with Sanofi -- REX-8756 is a potent and selective oral STAT6 inhibitor that demonstrates complete pathway inhibition and is well tolerated in preclinical studies --Investigational New Drug (IND)-enabling activities ongoing to support IND submission later this year SAN DIEGO, June 02, 2025 (GLOBE NEWSWIRE) -- Recludix Pharma, a leader in the discovery of inhibitors of challenging targets for infla ...